Adjusted pharmaceutical sales forecast in South Korea 2020, by drug type

Published by Statista Research Department, Jun 26, 2024
All types of drugs are expected to be affected to lesser or greater degrees by the COVID-19 outbreak in South Korea in 2020. Antiviral and respiratory drugs, along with those used for treating life-threatening conditions are expected to be the least affected. In contrast, drugs for non-urgent illnesses and conditions are expected to be most affected, as people stay away from hospitals if possible.

Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won)

CharacteristicSales in billion South Korean won
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Showing entries 1 to 13 (13 entries in total)
Statistic: Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won)

© Statista 2025
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

2020

Region

Worldwide

Survey time period

as of March 2020

Supplementary notes

Note: 1,000 South Korean won equal 0.82 U.S. dollars and 0.76 euros (as of May 2020).
Figures have been rounded.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Coronavirus: the pharma and medtech response "

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Coronavirus (COVID-19) in the Nordics Coronavirus (COVID-19) in FranceCoronavirus COVID-19 in ChinaCoronavirus disease (COVID-19) pandemicCoronavirus (COVID-19) in Italy
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.